Improving the spatial agglomeration level of regional pharmaceutical industry is an important measure to promote the competitive ability of national industry.We used three evaluation indicators,Spatial Gini Coefficient,Location Concentration Ratio and Agglomeration Index,was to calculate the degree and speed of regional agglomeration of pharmaceutical industry from 2011 to Oct 2015.At present,China's pharmaceutical industry has formed spatial concentration,particularly concentrates in Shandong,Jiangsu and Guangdong.And the chemical pharmaceutical industry mainly concentrates in Shandong, Jiangsu,Guangdong and Beijing;Chinese traditional medicine industry concentrates in Shandong,Sichuan,Jilin and Jiangxi;biopharmaceutical industry concentrates in Shandong,Jiangsu,Henan.From the point of view of development speed,the agglomeration speeds of bio-pharmaceutical and traditional medicine industry are accelerating compared with the shrink of chemical pharmaceutical industry.Three provinces of the greatest growing speed of agglomeration for chemical,traditional medicine and bio-pharmaceutical industry are Jilin,Tibet and Jiangxi, respectively.Agglomeration growth of biopharmaceutical industry in western region is prominent.This paper suggests that the national government should play a leading role in the development of regional cluster for pharmaceutical industry.Some effective measures should be taken which include formulating the supporting policies of enterprise cluster,establishing the incentive system of drug innovation and optimizing the industrial portfolio in order to promote the formation of regional sustainable competitive advantage through agglomeration effect.